Ocrelizumab 920mg/23ml solution for injection vials
NHS hospitals in England used £78,580,158 of indicative cost of Ocrelizumab 920mg/23ml solution for injection vials in the 12 months to July 2026, about 0.3% of all hospital medicines spend. That is up 259.8% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Ocrelizumab 920mg/23ml solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Ocrelizumab 920mg/23ml solution for injection vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| University College London Foundation Tr | £9,637,480 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £7,395,760 |
| Univ Hpl B/Ham Nhs Foundation Trust | £6,792,220 |
| Salford Royal Nhs Foundation Trust | £3,870,320 |
| Oxford University Hospitals Nhs Ft | £3,400,900 |
| King's College Hpl Nhs Foundation Trust | £3,170,980 |
| Sheffield Teaching Hospitals Nhs Trust | £2,931,480 |
| Western Sussex Hospitals Nhs Found Trust | £2,806,940 |
| Lancashire T/Ing Hsp Nhs Foundation Trus | £2,624,920 |
| University Hospital Southampton Nhs Ft | £2,596,180 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.